BeiGene, Ltd. Banner Image

BeiGene, Ltd.

  • Ticker BGNE
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BeiGene, Ltd. Logo Image
  • 1001-5000 Employees
  • Based in Cambridge, Massachusetts
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Their 4,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeuticsMore. They currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. They also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.
4.8 / 5.0 (86)

BeiGene, Ltd. reports have an aggregate usefulness score of 4.8 based on 86 reviews.

BeiGene, Ltd.

Most Recent Responsibility Report

BeiGene, Ltd.
MOST RECENT 2022 Environmental, Social, and Governance (ESG) Report

BeiGene, Ltd. does not currently have any hardcopy reports on ResponsibilityReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Archived Responsibility Reports

Our service enables potential investors to review the most recent and archived BeiGene, Ltd. Sustainability Report, BeiGene, Ltd. Corporate Social Responsibility Report, BeiGene, Ltd. CSR Report, BeiGene, Ltd. Corporate Responsibility, BeiGene, Ltd. CR Report, BeiGene, Ltd. Citizenship Report, BeiGene, Ltd. ESG Report, and BeiGene, Ltd. Environmental Report online.
BeiGene, Ltd. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!